PMID- 35992888
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220823
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Beneficial effects of preoperative superselective embolization on carotid body 
      tumor surgery: A 13-year single-center experience.
PG  - 930127
LID - 10.3389/fonc.2022.930127 [doi]
LID - 930127
AB  - PURPOSE: This study presented our 13-year experience managing patients with CBTs 
      (carotid body tumors) and was aimed to investigate the impact of pre-TAE 
      (preoperative transarterial embolization) on CBT surgical resection. METHODS: 
      This retrospective study reviewed 169 surgically excised CBTs between May 2007 
      and October 2020. According to whether to carry out the pre-TAE, the patients 
      were classified into the embolization (EG) (n = 130) and non-embolization groups 
      (NEG) (n = 39). Tumor classification was based on Shamblin criteria and tumor 
      size. The demographic data, clinical features, and intraoperative and 
      postoperative information about the patients were retrieved and analyzed. 
      RESULTS: The average tumor size was (43.49 vs. 35.44 mm, p = 0.04) for EG and 
      NEG. The mean surgical time (195.48 vs. 205.64 mins, p = 0.62) and intraoperative 
      BL (blood loss) (215.15 vs. 251.41 cc, p = 0.59) were less, but the incidence of 
      revascularization required (29% vs. 33%, p = 0.62) and total complications (26% 
      vs. 36%, p = 0.32) were lower in EG compared to NEG. Similarly, according to the 
      subgroup analysis, no significant differences were detected in the surgical time, 
      BL, adverse events (AEs), and the revascularization in EG when compared to NEG 
      for type I (n = 5 vs. 7), II (n = 105 vs. 27), and III (n = 20 vs. 5), 
      respectively except for the surgical duration in type III (p < 0.05). However, a 
      significantly lower incidence of AEs (230.25 vs. 350 cc, p = 0.038) and a decline 
      in BL (28.57% vs. 48.15%, p = 0.049) in EG were observed compared to those in NEG 
      patients for large CBTs (>/= 30 mm as the cutoff point). No surgery-related 
      mortality was observed during the follow-up. CONCLUSIONS: CBTs can be surgically 
      resected safely and effectively with a need for pre-TAE, which significantly 
      decreases the overall BL and AEs for large lesions (>/= 30 mm).
CI  - Copyright (c) 2022 Li, Wan, Chen, Yang, Chang and Huang.
FAU - Li, Nan
AU  - Li N
AD  - Department of Interventional Radiology, Guangzhou First People's Hospital, 
      Guangzhou, China.
FAU - Wan, Yuan
AU  - Wan Y
AD  - Interventional Center, the Sixth Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Interventional Radiology, the First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Yang, Jianyong
AU  - Yang J
AD  - Department of Interventional Radiology, the First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chang, Guangqi
AU  - Chang G
AD  - Department of Vascular Surgery, the First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Huang, Yonghui
AU  - Huang Y
AD  - Department of Interventional Radiology, the First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220805
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9389645
OTO - NOTNLM
OT  - blood loss
OT  - carotid body tumor
OT  - preoperative embolization
OT  - shamblin classification
OT  - surgical resection
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/23 06:01
PMCR- 2022/01/01
CRDT- 2022/08/22 04:35
PHST- 2022/04/27 00:00 [received]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/08/22 04:35 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/23 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.930127 [doi]
PST - epublish
SO  - Front Oncol. 2022 Aug 5;12:930127. doi: 10.3389/fonc.2022.930127. eCollection 
      2022.